Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 12:26 AM ET

Pharmaceuticals

Company Overview of Ascletis, Inc.

Company Overview

Ascletis, Inc., a specialty therapeutics company, discovers and develops treatments for cancer and infectious diseases. It provides ALN-VSP, a therapeutic comprising of siRNAs designed to target genes critical for the growth and development of cancer cells. The company has strategic partnerships with Alnylam Pharmaceuticals, Inc.; and Minsheng Pharma. Ascletis, Inc. was founded in 2011 and is based in Chapel Hill, North Carolina with operation sites in Hangzhou, China; and Research Triangle Park, North Carolina.

1002 Northridge Lane

Chapel Hill, NC 27514

United States

Founded in 2011

Phone:

919-928-5707

Key Executives for Ascletis, Inc.

Founder, Chairman, Chief Executive Officer and President
Founder and Director
Head of Discovery
Head of Business Development
Age: 51
Vice President of Research
Compensation as of Fiscal Year 2015.

Ascletis, Inc. Key Developments

Roche and Ascletis Enter Collaboration to Advance Treatment Options for Chinese Patients with Hepatitis C

Roche and Ascletis announced that they have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). It is estimated that over 10 million patients in China are chronically infected with HCV. The majority of these are genotype 1b, which has proven highly responsive to danoprevir. Roche and Ascletis are joining forces to develop a therapy with the potential to address a serious public health problem and to provide an effective new treatment option for Chinese patients with HCV. Under the terms of the agreement, Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau and receive payments upon reaching certain development and commercial milestones from Roche. Ascletis and Roche will collaborate for the clinical development and the commercialization. The contract also involves royalties.

Similar Private Companies By Industry

Company Name Region
Alva-Amco Pharmacal Companies, Inc. United States
Theracos, Inc. United States
Alliance Pharmaceutical Corp. United States
Ion Laboratories, Inc. United States
SynGlyco, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ascletis, Inc., please visit www.ascletis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.